GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (OTCPK:RKVTF) » Definitions » Return-on-Tangible-Asset

RKVTF (Rakovina Therapeutics) Return-on-Tangible-Asset : -337.22% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Rakovina Therapeutics Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Rakovina Therapeutics's annualized Net Income for the quarter that ended in Dec. 2024 was $-4.17 Mil. Rakovina Therapeutics's average total tangible assets for the quarter that ended in Dec. 2024 was $1.24 Mil. Therefore, Rakovina Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2024 was -337.22%.

The historical rank and industry rank for Rakovina Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:

RKVTF' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -323.36   Med: -230.49   Max: -134.8
Current: -323.36

During the past 4 years, Rakovina Therapeutics's highest Return-on-Tangible-Asset was -134.80%. The lowest was -323.36%. And the median was -230.49%.

RKVTF's Return-on-Tangible-Asset is ranked worse than
94.26% of 1497 companies
in the Biotechnology industry
Industry Median: -37.3 vs RKVTF: -323.36

Rakovina Therapeutics Return-on-Tangible-Asset Historical Data

The historical data trend for Rakovina Therapeutics's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics Return-on-Tangible-Asset Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
-179.78 -128.90 -309.21 -277.30

Rakovina Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -322.03 -696.09 -297.45 -257.95 -337.22

Competitive Comparison of Rakovina Therapeutics's Return-on-Tangible-Asset

For the Biotechnology subindustry, Rakovina Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rakovina Therapeutics's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Rakovina Therapeutics's Return-on-Tangible-Asset falls into.


;
;

Rakovina Therapeutics Return-on-Tangible-Asset Calculation

Rakovina Therapeutics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-2.859/( (0.472+1.59)/ 2 )
=-2.859/1.031
=-277.30 %

Rakovina Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Sep. 2024 )(Q: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Sep. 2024 )(Q: Dec. 2024 )
=-4.168/( (0.882+1.59)/ 2 )
=-4.168/1.236
=-337.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2024) net income data.


Rakovina Therapeutics  (OTCPK:RKVTF) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Rakovina Therapeutics Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Rakovina Therapeutics Business Description

Traded in Other Exchanges
Address
595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC, CAN, V6B 0A5
Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some of its products in the pipeline include kt-2000 AI, kt-3000 series. Rakovina gained exclusive use of the Deep Docking AI Platform, enabling it to significantly speed up identifying potential drugs for DNA damage response.